How to read a peptide study in five questions

Most claims you’ll see about peptides trace back to a real study. The question is what kind of study, and how far its results can be stretched. These five questions do most of the work.

1. Who — or what — was studied?

Results in a dish of cells or in rats are where research starts, not where it ends. Many compounds that work in animals fail in people. On Peptide World, every compound carries an evidence ladder that shows the highest rung its research has reached:

• In vitro — cells or tissue in a lab.
• Animal — usually rodents.
• Human pilot — small, often uncontrolled studies in people.
• Human RCT — randomized controlled trials, the strongest routine test of whether something works.

2. Was there a fair comparison?

Improvement after a treatment doesn’t prove the treatment caused it — people often get better anyway. Look for a control group (placebo or standard care), randomization (chance decides who gets what) and blinding (participants and researchers don’t know who got what).

3. How many people, for how long?

A study of 12 people for four weeks can suggest a question worth asking. It can’t establish safety or rare side effects. Large trials run for months or years are what regulators rely on.

4. What was actually measured?

A change in a blood marker or a gene-expression signal is not the same as people feeling better or living longer. Be wary when a surrogate marker is presented as a health outcome.

5. Who paid, and has anyone repeated it?

Industry funding doesn’t make a study wrong, but it’s worth knowing. More important is replication: has an independent group found the same thing? Registered trials on ClinicalTrials.gov ↗ also let you check whether the published results match what was planned.